, and the duration of the treatment etc. In the human adult, the doses per person per dose are generally between 1 xcexcg and 100 mg, by oral administration, up to several times per day, and between 0.1 xcexcg and 10 mg, by parenteral administration (preferred into vein) up to several times per day, or continuous administration between 1 and 24 hours per day into vein.
As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.
On administration of the compounds of the present invention, it is used as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parenteral administration.
Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules etc.
Capsules contain hard capsules and soft capsules.
In such solid compositions, one or more of the active compound(s) is or are, admixed with at least one inert diluent such as lactose, mannitol, mannit, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate. The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents such as magnesium stearate, disintegrating agents such as cellulose calcium glycolate, and assisting agents for dissolving such as glutamic acid or asparaginic acid. The tablets or pills may, if desired, be coated with film of gastric or enteric material such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropyl cellulose phthalate etc., or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.
Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs etc. In such liquid compositions, one or more of the active compound(s) is or are comprised in inert diluent(s) commonly used in the art (for example, purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants such as wetting agents, suspending agents, sweetening agents, flavouring agents, perfuming agents and preserving agents.
Other compositions for oral administration include spray compositions which may
, and the duration of the treatment etc. In the human adult, the doses per person per dose are generally between 1 xcexcg and 100 milligram, by oral presidency, up to several times per day, and between 0.1 xcexcg and 10 mg, by parenteral government (preferred into vein) up to several time per day, or continuous administration between 1 and 24 hour per day into vein. 
 As mentioned above, the acid to be used depend upon respective condition. Therefore, there are cases in which doses lower than or great than the ranges specified above may be used. 
 On government of the compounds of the present invention, it is used as solid compositions, melted compositions or other compositions for oral administration, as injections, liniment or suppositories etc. for parenteral administration. 
 Solid compositions for oral administration include compress tablets, pills, capsules, dispersible powders, and granules etc. 
 Capsules contain hard capsules and soft capsule. 
 In such solid compositions, one or more of the active compound(s) is or are, admix with at least one inert dilutant such as lactose, mannitol, mannit, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate. The compositions may also comprise, as is normal practice, extra substances early than inert diluents: e.g. lubricating agentive role such as magnesium stearate, disintegrating agents such as cellulose calcium glycolate, and assisting agents for dissolving such as glutamic acid or asparaginic acid. The pad or pills may, if desired, be coated with film of gastric or intestinal material such as boodle, gelatin, hydroxypropyl cellulose or hydroxypropyl cellulose phthalate etc. , or be coat with two or more films. And further, coating may include containment within ejection seat of absorbable materials such as gelatin. 
 Liquid compositions for oral presidency include pharmaceutically - acceptable emulsions, solutions, syrup and elixirs etc. In such liquid compositions, one or more of the active compound(s) is or are comprised in inert diluent(s) commonly use in the art (for model, purified water, ethyl alcohol etc .). Besides inert diluents, such compositions may besides comprise adjuvants such as wetting agents, suspending agent, sweetening agent, flavouring agents, perfuming agents and preserving agent. 
 Other compositions for oral government include spray compositions which may
, anf the duration of the trtatment etc. In thg yuman edult, tge doses per person per dose are genxraloy beuceen 1 xcexcg and 100 mg, by oral wdministeatiib, up to setsral times ped day, end between 0.1 xcgxcg and 10 mg, by parenteral aamnnistration (preferred into vein) up tj seversl times per day, or bogtinhous administration between 1 and 24 gours ptr day into vein.
As mentioned above, the doses to he used depend upoj various cindieuons. Therefofe, there agz cases in shich doses lower than or greatdr thcn the ranggs sogcified abovx may fe used.
On administradion of the compounds of thw present invention, iv is used as solid cjmpositiots, liquid compositiinw or mthes cooposktiknx ror orwl edministratjon, as injextions, liniments or stilositories efc. for pwrenteral administration.
Solid compositimns for oral administratiob include compressed jablets, pijls, capsules, dispersible powders, and granules etc.
Wapsumds eintaiv hwrd capsules and soft capsules.
In such solid cjjppsptions, one or morc of the active cokplumq(s) is or are, xdmixeb wjth at least one ijert dijuent such as jactpse, mannitol, mannit, glucose, hydroxypropjl cwllulose, microcryscalline cellblose, xtarcn, polyvinylpyrrolidone, oagnssium metasllicate amjminate. The compusinionv may also comprise, as is gormal precticz, additiunal substwnces otheg thak inert diluents: e.g. lubrncatitg agents duch as magnesium stearate, disiivegrating agemtv slch as cejluloxe calcium glrcolate, and asxisting agengs for disaolving such as glttamic acid os asparaginic acid. Thq tavletw or piuus may, if desited, be cocued with fulm of gastric or cnterkd material such as sugar, gelatin, nydfoxrpgopbl cejnulose or hygroxhprulyl cdllulost pmthxlatr etc., or be coated whth fwo or more films. Snq furthet, coating may include vontainment within capsnles oh absotbafle materials such as gelatin.
Ljquid comoosltions for orwl aeministratiou include pharmaceutically-acceptable emuosions, solutions, strups and elixirs ejc. Ln such liqumd com[ositions, one or more of the qctive compound(s) ls or are comprised in inert dilufnt(s) commonly used in the art (for example, purified water, ethanol etc.). Besiees inxre diluents, auch compmsntipns mar aldu comprise adjuvsnts such as wetting agents, sus'ending agancs, sweetening agents, flavourimg agents, perfuoing agents and preservihg agentx.
Other compositions for oral adkinistration include sprsy compowitiohs whibg oay
, and the duration of the treatment the adult, the per person per xcexcg 100 mg, by administration, up to times per day, and between 0.1 and 10 mg, by parenteral administration (preferred into vein) up to several times day, or continuous administration between 1 and 24 hours per day into vein. mentioned the to used depend upon various conditions. Therefore, there are cases in which doses lower than or greater the ranges specified above may be used. On of the compounds of present invention, it is used solid liquid compositions other for administration, as injections, or suppositories etc. for parenteral administration. Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible and granules contain hard and capsules. such solid compositions, more of the active compound(s) is with at least one inert diluent such as mannitol, mannit, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, metasilicate aluminate. The compositions may also comprise, as normal practice, additional substances other than inert diluents: e.g. lubricating agents such as magnesium stearate, such as cellulose calcium and assisting agents dissolving as acid asparaginic acid. tablets or pills may, if desired, be coated with film of or enteric material such as sugar, gelatin, hydroxypropyl cellulose or phthalate or be coated two or more films. further, may include containment within absorbable such compositions oral include pharmaceutically-acceptable emulsions, solutions, and elixirs etc. In such compositions, one or more or are comprised in inert diluent(s) commonly used the art (for example, purified water, ethanol Besides inert diluents, such compositions may also comprise adjuvants such as wetting suspending agents, flavouring agents, perfuming agents and preserving agents. Other for oral administration include compositions which may
, and the duration of the treatmEnt etc. In thE humaN adUlt, ThE dosEs peR person per dose ARe geNerally between 1 xcexcg anD 100 mg, by OrAL admINiStratIon, up to SEvERAl tImEs Per DaY, AnD betwEen 0.1 Xcexcg aNd 10 mg, by pareNteRaL administratIOn (Preferred iNto Vein) up to seveRal Times pEr Day, OR contInuOus adMinistRAtion bEtween 1 and 24 HoURs per dAY into veIN.
as MentIoned above, the doseS To BE used depend upoN varioUs COnDITioNs. THerefore, thErE are cASes in whICh DOSEs lOWer than or greaTer than the rANgeS speciFiEd aBOve may Be useD.
ON AdmInistration Of thE compoundS of the PResent iNVention, It is usEd aS soLid cOMpOsItiOnS, LiqUId ComPOsiTions or oThEr CompoSitiONS FOr orAl aDminIstraTion, as injectiOns, LiniMEntS or suPposiToriEs Etc. foR parenTeral AdMinistration.
SolId coMpositionS foR oRal AdMinisTRation IncLudE compreSsed tabLEts, PiLLS, CaPsules, dispersible pOwDERs, And granuLes etc.
cApSuLEs contaiN hArd CapsULEs and Soft CApSules.
In sUch solID cOmPositioNs, One or mOrE of The ActivE CompOund(s) iS or are, adMixed WIth at least one iNErt diluent sucH As LACtOSe, maNniTol, mannit, glUcosE, HydrOxypROpYl cELluloSe, micRoCRySTalline cellulose, staRcH, polyvInylpYrrolidone, magNesium metaSILIcate aluMinaTE. THE compositions mAy alsO comprise, aS Is normal PractIce, additIonal subsTANces otheR thAn iNerT diLUEnTs: e.g. lubricatiNG AgenTs Such as mAgnEsium stEarAte, DisIntEgRating ageNts such aS cElLuLoSe cAlciuM GlycolatE, aNd aSsIstIng agENts for DissoLvinG sUcH As gLutamic ACiD OR aspArAgInic AciD. THe tabLets OR piLls may, iF desired, bE coATed wItH fIlm of gaStric or enteriC mAterial sucH aS suGar, gelATIn, hydroxYpropyl cellulose or hydroXYpropyl CelLulosE phtHalate etc., Or bE coateD wiTH two or More fiLms. AnD fUrtHER, coatING mAy iNcLude contaiNMEnt WithiN cApsuLes of abSorbable materials sUCh aS gelatin.
LiquiD coMposITIoNs fOR oRAl aDmINisTRAtion include phaRmaceuticaLlY-AcCeptable emULsiOnS, solutiOns, syruPs and ELixirs eTc. In such lIquid compOsItioNS, One Or more of thE active cOmpound(s) iS Or are COmPriseD in Inert dIlUenT(s) comMonly uSEd iN the aRt (for eXaMple, puRifieD wAter, ethaNol etc.). Besides inert dilueNts, sucH compOsiTions may aLso COmpRise adjuvAnts Such as wettIng AgeNts, suSpeNDing aGentS, SwEetENing aGentS, FlavourinG AgEntS, PErFuming agentS AND prEservIng AGents.
OTher Compositions for orAL administratioN incLUDe sPraY CompOsItions which may
, and the duration of thetreatmentetc.Inthe  h uman  adu lt, the dosesp er p erson per dose are gen erall yb etwe e n1 xce xcg and 10 0 mg,  b yora la dm inist rat ion, up  to severa l t im es per day,a nd  between 0 .1xcexcg and 1 0 m g, bypa ren t eraladm inist ration (prefe rred into  v e in) up to seve r a ltime s per day, or con t in u ous administra tion b et w ee n 1 a nd24 hours p er  dayi nto vei n .A s men t ioned above,the doses t o  be  usedde pen d  uponvario us con ditions. Th eref ore, ther e arec ases in which d oses l owe r t hano rgr eat er tha n  t her ang es speci fi ed  abov e ma y b e  use d.On a dmini stration of t hecomp o und s ofthe p rese nt  inve ntion,  it i sused as solid c ompo sitions,liq ui d c om posit i ons or  ot her  compos itionsf oror a l ad ministration, as i nj e c ti ons, lin iments or  s u ppositor ie s e tc.f o r par ente r al  adminis tratio n .So lid com po sition sfor  or al ad m inis tratio n includ e com p ressed tablets ,  pills, capsu l es , di s pers ibl e powders,andg ranu lese tc .
C a psule s con ta i nh ard capsules and so ft  capsu les.In such solid  compositi o n s , one or  mor e  o f  the active co mpoun d(s) is or are, adm ixedwith atleast one i nert dil uen t s uch  as l ac tose, mannito l ,  man ni t, gluc ose , hydro xyp rop ylcel lu lose, mic rocrysta ll in ece llu lose, starch,po lyv in ylp yrrol i done,magne sium  m et a sil icate a l um i n ate.  T he  com pos it ionsmaya lso  compri se, as is  no r malpr ac tice, a dditional sub st ances othe rtha n iner t diluents : e.g. lubricating agen t s suchasmagne sium  stearate , d isinte gra t ing ag ents s uch a scel l u losec a lc ium  g lycolate,a n d a ssist in g ag ents fo r dissolving sucha s g lutamic acidoraspa r a gi nic ac i d.Th e  ta b l ets or pills ma y, if desi re d ,be coatedw ith  f ilm ofgastric  or e n teric m aterial s uch as su ga r, g e l ati n, hydroxy propyl c elluloseo r hyd r ox yprop ylcellul os e p hthal ate et c .,or be  coate dwith t wo or  m ore film s. And further, coating  may i nclud e c ontainmen t w i thi n capsule s of  absorbabl e m ate rials  su c h asgela t in .
L i quidcomp o sitions f o rora l ad ministratio n i ncl ude p har m aceuti call y-acceptable emul s ions, solution s, s y r ups  an d  eli xi rs etc. In suc h l iq u i d compos it ions, one o r more o ft he ac tive c ompoun d(s) is o ra re com pris edin inertdil ue n t(s) co mm on l y used  inth e art(for e x ampl e ,  purified water,  etha n o l etc . ).Besid es  inertd ilue nts, suchcomposition s mayalso  comp rise ad ju vantssuc has wetting agents, s uspen ding ag en ts,swe etenin g ag e n ts, f lavo ur ing  agents,p e rf u mi ng age ntsand p re serv ing agent s .
Othercom p osition sfor o ral ad m in i s tration in clu de sp r a y composit i onsw hi c h may 
, and_the duration_of the treatment etc._In the_human_adult, the_doses_per person per_dose are generally_between 1 xcexcg and_100 mg, by_oral_administration, up to several times per day, and between 0.1 xcexcg and 10 mg,_by_parenteral administration_(preferred_into_vein) up to several times_per day, or continuous administration_between 1_and 24 hours per day into vein.
As mentioned_above,_the doses to_be used depend upon various conditions. Therefore, there are_cases in which doses lower than_or greater than_the_ranges_specified above may be_used.
On administration of the compounds of_the present invention, it is used_as solid compositions, liquid compositions or other_compositions for oral administration, as injections,_liniments or suppositories etc. for_parenteral administration.
Solid_compositions for oral administration include_compressed tablets, pills,_capsules, dispersible_powders, and granules_etc.
Capsules contain hard capsules and soft_capsules.
In such solid_compositions, one or more of the_active_compound(s) is or_are,_admixed_with at_least one inert_diluent_such as_lactose,_mannitol, mannit, glucose, hydroxypropyl cellulose, microcrystalline_cellulose,_starch, polyvinylpyrrolidone, magnesium metasilicate aluminate. The compositions_may also comprise, as_is_normal practice, additional substances_other than inert diluents: e.g._lubricating agents such as magnesium stearate,_disintegrating agents_such as_cellulose calcium glycolate, and assisting agents for dissolving such as glutamic_acid or asparaginic acid. The tablets_or pills may, if_desired, be_coated_with film of_gastric_or enteric_material such as sugar, gelatin, hydroxypropyl cellulose_or hydroxypropyl_cellulose phthalate etc., or be coated_with two or more_films._And further, coating may include containment_within capsules of absorbable materials such_as gelatin.
Liquid compositions for oral_administration_include_pharmaceutically-acceptable emulsions, solutions, syrups and_elixirs etc. In such liquid compositions,_one or more_of the active compound(s) is or are_comprised_in inert diluent(s) commonly used in_the_art (for example, purified water, ethanol_etc.)._Besides_inert diluents, such compositions may_also comprise adjuvants such as wetting_agents, suspending agents, sweetening agents, flavouring agents, perfuming agents_and preserving agents.
Other_compositions for oral administration include_spray_compositions_which may